Aaron Gorin has over 10 years of experience in strategic, financial, and operational analysis of public and private Healthcare companies. Most recently, Mr. Gorin was the Director of Research at the Juvenile Diabetes Cure Alliance, a non profit devoted to finding and promoting research towards, a Practical Cure for Type 1 Diabetes. Prior to this, Mr. Gorin was a Healthcare Equity Research Analyst at Morgan Stanley and Bank of America/Merrill Lynch for 7 years where he focused on Biotech, Life Science Tools, Diagnostics, and Healthcare Services companies, including both domestic and international equities, as well as cap ranges from $50m-$50b. During his tenure, Mr. Gorin was instrumental in initiation of coverage reports on several high profile IPOs, and was involved in analysis of highly complex situations including poison pill takeovers, contentious proxy battles, leveraged buyouts, and activist campaigns. Prior to that, Mr. Gorin was a management consultant and a venture capitalist focusing on Life Science Investments at a privately held firm in New York. In this capacity, Mr. Gorin screened and triaged hundreds of potential deal targets including both compound-related and company-related transactions for acquisition as part of a Venture Fund, and worked on projects presenting to C-level management at Top 10 Global Pharmaceutical companies. Mr. Gorin graduated from Cornell University with an MHA in Health Economics and Administration and a BA in Economics.